In 2025, Hong Kong recorded a market value worth USD 1.64 billion.
The Hong Kong Infusion Services Market to total USD 2.88 billion by 2033, achieving a CAGR of 7.3% across the forecast period.
Compact, high-efficiency public hospitals maintain strong biologic infusion throughput, supported by structured reimbursement and disciplined specialty drug access.
Hong Kong Cancer Registry figures indicate sustained treated cancer prevalence, supporting consistent systemic therapy administration across Hospital Authority facilities.
DataCube Research Report (Feb 2026): This analysis uses 2024 as the actual year, 2025 as the estimated year, and calculates CAGR for the 2025-2033 period.
*Research Methodology: This report is based on DataCube’s proprietary 3-stage forecasting model, combining primary research, secondary data triangulation, and expert validation.
[Learn more]